[1] Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol, 2013, 28 Suppl 1:11-17.
[2] Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int, 2017, 37 Suppl 1:81-84.
[3] Day CP, James OF. Steatohepatitis: a tale of two "hits". Gastroenterology, 1998, 114:842-845.
[4] Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression Biochem Soc Trans 2008, 36:1224-1231.
[5] Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks. J Mol Biol 2013, 425:3582-3600.
[6] Liu XL, Cao HX, Fan JG. MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease. J Dig Dis. 2016, 17:708-715.
[7] Shibata C, Kishikawa T, Otsuka M, et al. Inhibition of microRNA122 decreases SREBP1 expression by modulating suppressor of cytokine signaling 3 expression. Biochem Biophys Res Commun, 2013, 438:230-235.
[8] Akuta N, Kawamura Y, Suzuki F, et al. Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterology, 2016, 16:141.
[9] Tsai WC, Hsu SD, Hsu CS, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest, 2012, 122:2884-2897.
[10] Liu XL, Pan Q, Zhang RN, et al. Disease-specific miR-34a as diagnostic marker of nonalcoholic steatohepatitis in a Chinese population. World J Gastroenterol. 2016 Nov 28;22:9844-9852.
[11] Xu Y, Zalzala M, Xu J, et al. A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. Nat Commun, 2015, 6:7466.
[12] Shan W, Gao L, Zeng W, et al. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease. Cell Death Dis, 2015, 6:e1833.
[13] Ferreira DM, Afonso MB, Rodrigues PM, et al. c-Jun N-Terminal Kinase 1/c-Jun activation of the p53/MicroRNA34a/Sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol Cell Biol, 2014, 34:1100-1120.
[14] Panera N, Gnani D, Crudele A, et al. MicroRNAs as controlled systems and controllers in nonalcoholic fatty liver disease. World J Gastroenterol, 2014, 20:15079-15086.
[15] Ding J, Li M, Wan X, et al. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease. Sci Rep, 2015, 5:13729.
[16] Gerin I, Clerbaux LA, Haumont O, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem. 2010, 285:33652-33661.
[17] Li T, Francl JM, Boehme S, et al. Regulation of cholesterol and bile acid homeostasis by the CYP7A1/SREBP2/miR-33a axis. Hepatology, 2013, 58: 1111-1121.
[18] Allen RM, Marquart TJ, Albert CJ, et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med, 2012, 4:882-895.
[19] Goedeke L, Vales-Lara FM, Fenstermaker M, et al. A regulatory role for microRNA 33* in controlling lipid metabolism gene expression. Mol Cell Biol, 2013, 33:2339-2352.
[20] Aranda JF, Madrigal-Matute J, Rotllan N, et al. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. Free Radic Biol Med, 2013, 64:31-39.
[21] Takeuchi-Yorimoto A, Yamaura Y, Kanki M, et al. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease. Toxicol Lett. 2016, 258:159-167.
[22] Sun C, Huang F, Liu X, et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J Mol Med. 2015, 35:847-853.
[23] Wu H, Ng R, Chen X, et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut. 2016, 65:1850-1860.
[24] Loyer X, Paradis V, Hénique C, et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut. 2016, 65:1882-1894.
[25] Lin X, Jia J, Du T, et al. Overexpression of miR-155 in the liver of transgenic mice alters the expression profiling of hepatic genes associated with lipid metabolism. PLoS One. 2015, 10:e0118417.
[26] Virtue A, Johnson C, Lopez-Pastraa J, et al. MicroRNA-155 deficiency leads to decreased atherosclerosis, increased white adipose tissue obesity, and non-alcoholic fatty liver disease: A novel mouse model of obesity paradox. J Biol Chem. 2017, 292:1267-1287.
[27] Wang L, Zhang N, Wang Z, et al. Decreased MiR-155 level in the peripheral blood of non-alcoholic fatty liver disease patients may serve as a biomarker and may influence LXR activity. Cell Physiol Biochem. 2016, 39:2239-2248.
[28] Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int, 2014, 2014:741465. |
